Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer

JAMA Netw Open. 2024 Jul 1;7(7):e2424855. doi: 10.1001/jamanetworkopen.2024.24855.
No abstract available

Plain language summary

This cohort study examines the association of low-dose vs high-dose 5-fluorouracil with overall survival when used in triplet chemotherapy plus bevacizumab in patients from the metastatic colorectal cancer (CRC).

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bevacizumab* / administration & dosage
  • Bevacizumab* / therapeutic use
  • Colorectal Neoplasms* / drug therapy
  • Dose-Response Relationship, Drug
  • Female
  • Fluorouracil* / administration & dosage
  • Fluorouracil* / therapeutic use
  • Humans
  • Male
  • Middle Aged

Substances

  • Bevacizumab
  • Fluorouracil